Place of Long-Acting β-Agonists in Asthma not Controlled by Corticosteroids

Greening, A P

doi:10.1007/bf03259339

Clin. Immunother.

1996

DOI: 10.1007/bf03259339

|View full text |Cite

Place of Long-Acting β-Agonists in Asthma not Controlled by Corticosteroids

A P Greening

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1997

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

et al. 2023

View full text Add to dashboard Cite

Several current guidelines/strategies outline a treatment approach to asthma, which primarily consider the goals of improving lung function and quality of life and reducing symptoms and exacerbations. They suggest a strategy of stepping-up or down treatment, depending on the patient's overall current asthma symptom control and future risk of exacerbation. While this stepwise approach is undeniably practical for daily practice, it does not always address the underlying mechanisms of this heterogeneous disease. In the last decade, there has been an attempt to improve the treatment of severe asthma such as the addition of long-acting antimuscarinic agent to the traditional ICS/LABA treatment, and the introduction of therapies targeting key cytokines. However, despite such strategies several unmet needs in this population remain, motivating research to identify novel targets and develop improved therapeutic and/ or preventative asthma treatments. Pending the availability of such therapies, it is essential to re-evaluate the current conventional 'one-size-fits-all' approach to a more precise asthma management. Although challenging, identifying 'treatable traits” that contribute to respiratory symptoms in individual patients with asthma may allow a more pragmatic approach to establish more personalized therapeutic goals.

show abstract

Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

et al. 2023

View full text Add to dashboard Cite

show abstract

Management of Asthma

Davis¹,

Noble²

1997

Disease Management & Health Outcomes

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Place of Long-Acting β-Agonists in Asthma not Controlled by Corticosteroids

Cited by 2 publications

References 79 publications

Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

Management of Asthma

Contact Info

Product

Resources

About